GILEAD SCIENCES INC

Their core work

Gilead Sciences is a major US-based biopharmaceutical company specializing in antiviral therapeutics, with commercial franchises in HIV, hepatitis B and C, and emerging work in liver disease and oncology. In their H2020 engagements they contribute industry-grade clinical development capability, access to proprietary compounds, and expertise in viral persistence, immune therapy, and liver pathophysiology. Their value to European consortia is less academic theory and more translational muscle: they help move biomarker and immune-modulation hypotheses toward clinical testing. For scientists, they are a partner that can take findings from bench into patients; for businesses, a name that lends credibility to any health-research collaboration.

What they specialise in

How they've shifted over time

In the earlier H2020 period (2016-2017 entries), Gilead's European footprint centered on broader infectious disease themes — patient susceptibility, microbiome, vaccines and antimicrobial resistance — alongside liver biomarker qualification in LITMUS. By the more recent period (2020 onward) their engagement sharpened toward chronic viral hepatitis cure strategies and immune-based therapeutics, with IP-cure-B explicitly targeting HBV cure. The shift mirrors Gilead's corporate strategy: moving from broad anti-infective participation to curative, immunology-driven antiviral programs.

They are moving deeper into functional-cure strategies for chronic viral infections, making them a strong industry partner for any consortium working on host-directed immune therapy or HBV/HCV/HDV endpoints.

How they like to work

Gilead joins European projects as an industry partner or third party, never as coordinator — which is typical for a US-headquartered pharma operating inside EU frameworks. Their projects are large, multi-country consortia (97 unique partners across 22 countries), suggesting they prefer high-visibility flagship programs over small bilateral collaborations. Working with them means entering a structured industry-academia relationship where they contribute compounds, clinical expertise and regulatory know-how rather than lead management.

Connected to 97 distinct consortium partners across 22 countries through only three projects, indicating participation in unusually large, pan-European health flagships. The network centers on Western European academic medical centers and other pharma companies active in hepatology and infectious disease.

What sets them apart

Gilead is one of a small handful of global antiviral leaders, and the undisputed commercial leader in HIV and hepatitis B therapy — which makes their presence in a consortium a signal that the science has real clinical and market traction. Unlike most European academic partners, they bring proprietary antiviral and immunomodulatory molecules, global clinical trial infrastructure, and a regulatory track record with EMA and FDA. If a project needs an industry sponsor who can actually carry a compound from biomarker to registered therapy in liver or infectious disease, they are a top-tier choice.

Highlights from their portfolio

• IP-cure-B
  A flagship HBV functional-cure consortium aligned exactly with Gilead's strategic antiviral pipeline, running into 2025.
• LITMUS
  One of Europe's largest NASH/NAFLD biomarker qualification programs — a rare public-private platform directly relevant to liver-disease drug development.
• PRONKJEWAIL
  Unusual multi-topic project combining microbiome, vaccines and antimicrobial resistance in immunocompromised patients, showing Gilead's reach beyond antivirals.